Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, ...

Original research: Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group ...

2. CD19 靶点治疗：CD19 是 B 细胞的特异性表面标记之一 ... 使自身抗体水平迅速下降。贝利尤单抗（belimumab）是一种抗 BAFF 单克隆抗体，对 SLE 有效。在 IIM 患者中，BAFF 水平与 CK 水平相关，血清 BAFF 水平在 MDA5 + DM 患者中显著高于 ASS 患者和健康对照，且在合并 ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. Now, the U.K.-based pharma is overseeing a range of clinical trials to ...

Lead program obexelimab is designed to bind to CD19 and Fc gamma receptor IIb, both of them targets expressed on B cells. A Phase 3 test is underway in immunoglobulin G4-related disease ...

Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to disease pathogenesis. In this phase 3, double-blind, randomized, placebo-controlled trial, we enrolled ...

Credit: Getty Images In a phase 3 clinical trial, researchers assessed the efficacy and safety of inebilizumab in patients with generalized myasthenia gravis. At Week 26, compared to the placebo ...

The CD19/20-targeting CAR-T asset IMPT-314—which Lyell is testing across two different treatment lines of aggressive B-cell non-Hodgkin lymphoma—was the primary motivating factor behind Lyell ...

IMPT-314 is a dual-targeting CD19/20 CAR T cell candidate for hematologic malignancies, including B-cell non-Hodgkin’s lymphoma. Lyell had 300 overall employees as of Dec. 31, according to a March 11 ...

Anti-CD47 or Aβ inhibitor restore immunity, reduce bacterial load/organ damage, and improve survival. Downregulated adaptive immunity genes (e.g., Pax5, CD19) potentially distinguish sepsis from ...

Inebilizumab-cdon is the first FDA-approved treatment for IgG4-related disease, targeting CD19+ B cells to reduce inflammation and fibrosis. The MITIGATE trial showed inebilizumab significantly ...